Clinical Trials Logo

Mucosal Lentiginous Melanoma clinical trials

View clinical trials related to Mucosal Lentiginous Melanoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT01395121 Completed - Clinical trials for Acral Lentiginous Malignant Melanoma

A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread

NICAM
Start date: December 2009
Phase: Phase 2
Study type: Interventional

The aim of this study is to see if a drug called nilotinib (Tasigna®) is effective in the treatment of patients with a rare group of acral and mucosal melanomas that have a change (mutation) in a protein called cKIT. Nilotinib interferes with signalling inside cells with this mutation and it is believed that this may lead to shrinkage of tumours. Acral melanomas are found on the palms and soles and mucosal melanomas start inside body cavities rather than on the skin.

NCT ID: NCT00788775 Completed - Melanoma Clinical Trials

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Start date: January 23, 2009
Phase: Phase 2
Study type: Interventional

Given the poor prognosis and limited treatment options available for patients with mucosal or acral/lentiginous melanomas who develop metastatic disease, genetic discoveries of KIT mutations in these cancers present the need to test multi-targeted kinase inhibitors with potent KIT inhibitory activity in this patient population. Imatinib and other tyrosine kinase inhibitors (TKIs) have the potential to be effective in this patient population, but patients may develop resistance to treatment. Therefore, in this study, we propose to test nilotinib in patients with metastatic mucosal, acral, or chronically sun-damaged melanoma following treatment with another TKI.

NCT ID: NCT00577382 Active, not recruiting - Clinical trials for Acral Lentiginous Malignant Melanoma

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Start date: August 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate how effective SU011248 works in treating acral lentiginous and mucosal melanoma which has spread beyond the local region. SU011248 is a protein-tyrosine kinase inhibitor and acts as a c-kit inhibitor drug. It is believed to work by blocking signals on certain cancer cells which allow the malignant cells to multiply and spread due to a change in the genetic make up of the cancer cell.